Clinical Trials › NCT06617793
RecruitingPhase 1
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
Sponsored by Novartis Pharmaceuticals
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 28
Target enrollment
Feb 2025
Start date
Oct 2030
Expected completion
Interventions / Treatments
rapcabtagene autoleucel (YTB323)
Conditions studied
Relapsing Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 1 trials
Browse all Phase 1 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.